On Monday, Following U.S. Stocks were among the “Top Gainers“:Penn Virginia Corporation (NYSE:PVA), Boston Scientific Corporation (NYSE:BSX), Amicus Therapeutics, Inc (NASDAQ:FOLD), AmerisourceBergen Corp (NYSE:ABC)
Penn Virginia Corporation (NYSE:PVA)’s shares picked up 4.06%, and closed at $7.18.. The stock has price to sale ratio of 1.00, however, price to book ratio is 0.77. With recent incline, the year-to-date (YTD) performance reflected a 7.49% gain above last year. During the past month the stocks gain 4.06%, bringing three-month performance to 47.13% and six-month performance to -46.46%. The mean recommendation of analysts for this stock is 2.10. (where 1=Buy, 5=Sale).
Penn Virginia Corporation, an independent oil and gas company, explores, develops, and produces crude oil, natural gas liquids, and natural gas in various onshore regions of the United States. The company’s operations comprise the drilling of unconventional horizontal development wells in the Eagle Ford Shale in South Texas. It also has operations in the Granite Wash in Oklahoma, and the Haynesville Shale and Cotton Valley in East Texas. As of December 31, 2014, the company had proved oil and gas reserves of about 115 million barrels of oil equivalent; had 738 gross productive wells; and owned about 224,000 gross acres of leasehold and royalty interests. Penn Virginia Corporation was founded in 1882 and is headquartered in Radnor, Pennsylvania.
Boston Scientific Corporation (NYSE:BSX), raised 3.79%, and closed at $17.24, hitting new 52-week high of $17.42. The company holds the market capitalization of 22.10B. For the last twelve months, the stock was able to keep return on equity at -1.80%, while return on assets at - 0.70%, in response to its return on investment at 0.80%. Its 20-day moving average gained 4.41%, above 50-day moving average of 12.70%, above 200-day moving average of 29.12% from the latest market price of $17.24. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg. It offers interventional cardiology products, counting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, in addition to peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to diagnose and treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors.
Amicus Therapeutics, Inc (NASDAQ:FOLD), enhanced 3.78%, and closed at $9.60, hitting new 52-week high of $9.65. The stock volatility for the week is 6.03%, while for the month remained 5.16%. The company holds consensus target price of $12.50.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.93diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 19.80% and Annual EPS growth for the past 5 years is considered as -26.20%.
The mean recommendation of analysts for this stock is 1.50. (where 1=Buy, 5=Sale).
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs comprise next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I. It also develops pharmacological chaperone migalastat HCl as a monotherapy that has accomplished two Phase III global registration studies for Fabry disease; ATB200, a recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for the treatment of Parkinson’s disease. The company has planned partnership with GlaxoSmithKline PLC to develop and commercialize migalastat. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
AmerisourceBergen Corp (NYSE:ABC), rose 3.75%, and closed at $110.13, hitting new 52-week high of $110.20. The company has the market capitalization of $23.31B. The beta value of the stock is 0.66. On the other hand the stock’s volatility for the week is 1.62%, and for the month is 1.28%. The stock’s price to book ratio is $13.66, however price to sale ratio is $0.20. Analyst’s mean recommendation regarding this stock is 2.30. (where 1=Buy, 5=Sale).
AmerisourceBergen Corporation sources and distributes pharmaceutical products to healthcare providers, pharmaceutical and biotech manufacturers, and specialty drug patients in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, counting acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy administration, staffing, and other consulting services; scalable automated pharmacy dispensing equipment; medication and supply dispensing cabinets; and packaging solutions to institutional and retail healthcare providers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
